Neuronetics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed a quorum and re-elected all director nominees, ratified KPMG as auditor, and approved executive compensation and the 2026 Equity Incentive Plan. No questions were raised, and shareholders were thanked for their support.
-
Q1 2026 revenue grew 8% year-over-year to $34.5 million, with improved net loss and adjusted EBITDA. Clinic revenue rose 15% on strong SPRAVATO growth, while NeuroStar system sales increased but treatment revenue declined. Guidance and cash outlook remain stable.
Fiscal Year 2025
-
Q4 2025 saw 23% adjusted pro forma revenue growth and positive operating cash flow, driven by Greenbrook integration and strong clinic and NeuroStar performance. 2026 guidance projects >9% revenue growth, continued clinic expansion, and new therapy launches, with a focus on efficiency and profitability.
-
Q3 2025 revenue rose 101% year-over-year to $37.3M, driven by Greenbrook clinic growth and operational efficiencies. Gross margin declined due to business mix, but cash burn improved sharply. Full-year guidance was revised to $147–$150M, with positive cash flow targeted in Q4.
-
Q2 revenue surged 132% YoY to $38.1M, driven by Greenbrook integration and operational gains. Gross margin declined to 46.6% due to revenue mix, but cash flow improved and full-year revenue is guided at $149M–$155M. Positive momentum in adolescent treatments and BMP Program expansion.
-
Q1 2025 revenue surged 84% year-over-year to $32 million, driven by Greenbrook integration and strong clinic performance. SPRAVATO rollout, BMP program expansion, and adolescent TMS growth supported results, with cash flow positivity targeted for Q3 2025.
Fiscal Year 2024
-
Q4 2024 revenue rose 11% to $22.5M, driven by the Greenbrook acquisition and BMP program expansion. Gross margin declined due to clinic integration, but cost synergies and new capital support a positive cash flow outlook for Q3 2025.
-
Greenbrook acquisition is set to close soon, with over $22 million in cost synergies expected and most savings realized immediately. Utilization growth, expanded adolescent treatment, and improved reimbursement are key 2025 drivers.
-
Q3 2024 revenue grew 4% year-over-year to $18.5M, with gross margin up to 75.6%. The Greenbrook TMS acquisition is set to close in Q4, targeting $20M in annualized cost synergies and cash flow break-even by Q3 2025. Profitability is prioritized over top-line growth.
-
The conference highlighted a major acquisition, expanded treatment capabilities, and strong cost discipline. Revenue and operational synergies from the Greenbrook TMS deal are expected to drive growth, with a focus on improved reimbursement, expanded services, and a path to cash flow breakeven in 2025.
-
Q2 revenue fell 7% year-over-year to $16.5M due to Change Healthcare disruptions, but underlying utilization and demand remain strong. The company announced a transformative merger with Greenbrook TMS, expects mid-teens revenue growth and $15M+ in annual cost synergies post-merger, and reaffirmed its path to profitability.
-
New patient starts and utilization are accelerating, driven by the Better Me Provider Program and NeuroStar University training. The adolescent indication is expanding market reach, while prudent expense management supports a path to cash flow breakeven in 2025.